Accelerated TMS in 2026: SWIFT, 5×5 rTMS, and Faster Routes to Depression Remission

Standard rTMS for depression was designed in the late 1990s around the practical constraint of outpatient scheduling, not around neuroscience. One session per day, five days per week, four to six weeks — that cadence was convenient, not optimal. The question of how close in time those sessions need to be, and whether more daily sessions would be better or worse, was not rigorously answered for over two decades.

Three events changed that. First, the Stanford team showed that ten iTBS sessions in a single day, repeated over five days, produced ~90% remission in an open-label TRD cohort — a result that had no precedent in psychiatry. Second, BrainsWay published a randomised non-inferiority trial in 2026 showing that six half-day sessions of their deep TMS system matched standard daily deep TMS for both response and remission, while reaching remission faster. Third, a large retrospective analysis found that five standard rTMS sessions per day for five days achieved equivalent outcomes to six weeks of once-daily treatment. The field is moving.

This article covers what the 2026 evidence actually shows, how the main accelerated protocols differ, and how I think about patient selection — including the cases where I still prefer the slower, conventional approach.

Why Standard TMS Is 4–6 Weeks and Accelerated TMS Is 5–6 Days

Standard rTMS grew out of the original FDA pivotal trial design, in which patients received 10 Hz left prefrontal cortex stimulation for 37.5 minutes daily, five days per week, over approximately four to six weeks. That cadence was replicated by subsequent trials and embedded in coverage policies, not because evidence showed it was optimal but because it was the schedule that generated the pivotal approval data.

Theta burst stimulation changed the duration-per-session problem. Because iTBS delivers a full therapeutic dose in approximately three minutes rather than 37, it became mechanistically plausible to deliver multiple sessions in a day without running out of clinic hours. The inter-session interval is the key biological variable: animal data suggest that synaptic plasticity mechanisms (specifically long-term potentiation induction) can be re-triggered after as little as 50 minutes of recovery, which is the gap the SWIFT and 5×5 protocols use.

What accelerated TMS does not do is skip the total pulse count. The same cumulative number of pulses — roughly 50,000–72,000 over a course — is delivered; the difference is compression in time. Whether faster accumulation is equivalent, superior, or inferior to slower accumulation for long-term durability is still being studied.

SAINT and SNT: The Gold Standard for Accelerated TMS

The Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol, now FDA cleared and commercialised as Stanford Neuromodulation Therapy (SNT), established proof of concept for accelerated TMS in treatment-resistant depression.

The open-label study published in 2020 enrolled patients with severe TRD and delivered 10 sessions of iTBS per day for 5 days (50 sessions total), targeting the left dorsolateral prefrontal cortex subregion most anticorrelated with the subgenual anterior cingulate cortex — a site identified individually for each patient using resting-state fMRI. Results: approximately 90% of participants met remission criteria at day 5. Adverse effects were mild and transient [1].

The sham-controlled randomised trial published in 2022 enrolled 29 patients with moderate-to-severe TRD and found that active SNT outperformed sham on the primary outcome (MADRS score at four weeks). The double-blind design confirmed that the signal was not purely placebo, though the small sample size limits confidence in the effect-size estimate [2].

SAINT/SNT has two practical barriers. It requires resting-state fMRI for individualised targeting, which limits it to academic centres with that infrastructure. And it delivers 10 sessions per day — meaning the patient spends approximately 10 hours in the clinic each day for five days. That commitment is feasible for some but not all.

SWIFT: BrainsWay Accelerated Deep TMS (2025 FDA Clearance)

BrainsWay’s SWIFT protocol uses the FDA-cleared H1 deep TMS coil — the same hardware already used in their standard approved protocol for major depression and OCD — but restructures the delivery schedule. Where standard BrainsWay deep TMS delivers one session per weekday over six weeks, SWIFT delivers three sessions per day for two days (Saturday–Sunday) across three consecutive weekends, totalling six half-day clinic visits.

The pivotal evidence is a multisite randomised non-inferiority trial published in Brain Stimulation in March 2026 (doi: 10.1016/j.brs.2026.103050). The trial compared SWIFT directly against the standard once-daily BrainsWay protocol for major depressive disorder. Headline results: response rate 87.8% (SWIFT) versus 87.5% (standard), meeting the pre-specified non-inferiority margin. Remission was achieved at a median of 21 days in the SWIFT arm versus 28 days in the standard arm — a clinically meaningful seven-day advantage for a patient in acute distress.

A secondary analysis published in Journal of Affective Disorders in August 2026 (doi: 10.1016/j.jad.2026.122409) examined suicidal ideation as a specific endpoint. SWIFT reduced ideation at a median of 10 days; standard deep TMS took 13 days. For patients in whom suicidal ideation is the most urgent clinical concern, that three-day difference matters.

The practical appeal of SWIFT is that it does not require neuroimaging and runs on existing BrainsWay hardware. Any clinic already operating a BrainsWay H1 system can deliver SWIFT with a protocol update. FDA cleared SWIFT in September 2025.

The main limitation remains reimbursement. Medicare covers up to two TMS sessions per day; SWIFT’s three-sessions-per-day structure places it outside routine insurance coverage. Patients pay out of pocket for the compressed schedule, though the total number of sessions — and thus total cost — is comparable to the standard protocol.

5×5 Accelerated rTMS: The Evidence from 2026

The 5×5 protocol describes standard rTMS (10 Hz or comparable pulse trains) delivered five times per day over five consecutive working days, then followed by observation. Unlike SAINT, it does not require functional neuroimaging; unlike SWIFT, it does not require a specific deep TMS device. Any clinic with a standard TMS system can run it in principle.

A retrospective analysis published in Journal of Affective Disorders in 2026 (Apostol et al., doi: 10.1016/j.jad.2026.121345) compared 40 patients who received the 5×5 schedule with 135 patients who completed a conventional once-daily protocol. At the primary endpoint, symptom change did not differ significantly between groups (P = 0.07). The accelerated group included a subgroup that showed minimal change at day 5 but continued improving over the following four weeks — a pattern the authors describe as delayed responders and argue should not be labelled non-responders at the end of the five-day acute phase.

What 5×5 retrospective data cannot tell us is whether equivalent endpoint outcomes reflect equivalent mechanisms, equivalent durability, or simply equivalent noise in a small sample. Prospective randomised trials are needed. For now, 5×5 represents a reasonable pragmatic option for patients who cannot commit to six weeks of daily commuting, with the caveat that the evidence quality is substantially below the SWIFT randomised trial.

Comparison: SWIFT vs SAINT vs 5×5 vs Standard TMS

Who Is a Candidate for Accelerated Protocols?

Not every patient with treatment-resistant depression belongs in an accelerated schedule. Standard once-daily rTMS remains appropriate for most patients — it is covered, it is validated, and the slower pace allows weekly monitoring and protocol adjustments.

Accelerated TMS becomes the preferred approach in a narrower set of circumstances:

Acute suicidal ideation with hospitalisation risk. The seven-day faster remission with SWIFT, and the evidence of faster suicidality reduction, is the most compelling argument. A patient who needs six weeks to respond may need inpatient admission to remain safe; a patient who responds in three weeks may not. Ketamine IV can serve as a bridge to TMS response in this setting — not as a standalone treatment, but as short-term stabilisation while TMS takes effect. I do not recommend ECT in this context: newer evidence shows no efficacy advantage of ECT over rTMS or IV ketamine for depression, while the memory-erasure risk of ECT is real and permanent (Mathiassen 2026, British Journal of Psychiatry, PMID 40357797; Terao 2025, PCN Reports, PMID 40590032).

Patients who cannot attend daily for 4–6 weeks. Travellers, people in rural areas, patients with demanding caregiving responsibilities, and international patients at a specialised centre are realistic candidates for a compressed protocol.

After a completed diagnostic workup. I would not start any TMS — accelerated or standard — before ruling out treatable upstream causes of treatment resistance: unrecognised systemic inflammation (CRP, cytokine panel), occult infections (Lyme disease, Bartonella, reactivated EBV or HHV-6), and thyroid dysregulation. Accelerated TMS applied to a brain inflamed by an untreated Lyme infection is not going to produce SAINT-level remission rates.

Crisis routing: Readers experiencing acute suicidal ideation should contact emergency services or a crisis line immediately. Treatment decisions follow stabilisation.

Practical Guidance: Navigating Access and Cost

Accelerated TMS currently requires out-of-pocket payment in almost every setting. Medicare covers up to two TMS sessions per day, which allows some accelerated approaches (such as twice-daily conventional rTMS) but not five-per-day or three-per-day schedules. Prior authorisation for SWIFT as a novel protocol is in early stages at a small number of private payers.

For the SWIFT protocol, patients need a clinic with a BrainsWay H1 system that has updated its protocol to the SWIFT schedule — not all BrainsWay centres have done so. For SAINT/SNT, the prerequisite is a centre with a 3T MRI scanner and software to generate individualised targeting coordinates.

A reasonable approach for most patients remains: begin with insurance-covered once-daily rTMS, complete at least 20 sessions to assess trajectory, and escalate to an accelerated protocol only if the initial response is insufficient or the clinical urgency is high.

Related Articles

• TMS for Depression: What 20 Years of Evidence Shows — foundational evidence, standard protocols, response rates, and patient selection
• Treatment-Resistant Depression: The Cause-First Workup Before TMS — Julian’s workup sequence: qEEG, inflammation, infections, relationships
• What Is TMS? Transcranial Magnetic Stimulation Explained — TMS vs TPS, FDA clearance history, mechanism of action
• Ketamine Infusion Therapy: Clinical Evidence and Protocol — when ketamine serves as a bridge in acute depression
• ECT: Side Effects, Memory Loss, and the Alternatives Julian Recommends — why Julian opposes ECT and what the evidence shows